Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is taking its cardiovascular risk assessment solutions directly to benefits decision-makers this June, participating in four national benefits conferences to discuss strategies for reducing the financial burden of heart disease on employers and insurers.
Cardiovascular disease remains one of the most expensive health conditions in the United States, according to the American Heart Association. Direct healthcare costs for cardiovascular disease accounted for approximately 11% of all U.S. healthcare expenditures in 2020–2021, more than any other major diagnostic group. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient's health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses.
The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. By identifying high-risk individuals before an event occurs, Cardio Diagnostics aims to help organizations avoid the substantial costs associated with late-stage disease management.
Cardio Diagnostics' participation in these conferences comes at a time when employers and insurers are increasingly seeking data-driven approaches to manage healthcare spending. The company's technology offers a way to stratify risk among employee populations, potentially allowing for more efficient allocation of wellness resources and preventive care programs.
For more information about Cardio Diagnostics and its latest news, visit the company's newsroom at https://nnw.fm/CDIO.
